Mackenzie Financial
ACAD icon

Mackenzie Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Mackenzie Financial’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
420,825
+319,488
+315% +$7.03M 0.01% 619
2026
Q1 		$2.26M Buy
101,337
+44,063
+77% +$1.05M ﹤0.01% 897
2025
Q4 		$1.53M Buy
57,274
+3,917
+7% +$93.6K ﹤0.01% 950
2025
Q3 		$1.14M Hold
53,357
– – ﹤0.01% 1033
2025
Q2 		$1.15M Sell
53,357
-5,022
-9% -$93.3K ﹤0.01% 980
2025
Q1 		$970K Buy
58,379
+7,314
+14% +$133K ﹤0.01% 991
2024
Q4 		$937K Buy
51,065
+32,833
+180% +$530K ﹤0.01% 954
2024
Q3 		$280K Sell
18,232
-1,668
-8% -$27.8K ﹤0.01% 1223
2024
Q2 		$323K Sell
19,900
-37,839
-66% -$611K ﹤0.01% 1144
2024
Q1 		$1.07M Buy
57,739
+4,760
+9% +$118K ﹤0.01% 863
2023
Q4 		$1.66M Buy
52,979
+39,460
+292% +$942K ﹤0.01% 763
2023
Q3 		$281K Sell
13,519
-10,143
-43% -$275K ﹤0.01% 1161
2023
Q2 		$568K Buy
23,662
+10,325
+77% +$230K ﹤0.01% 983
2023
Q1 		$251K Sell
13,337
-1,254
-9% -$23.9K ﹤0.01% 1256
2022
Q4 		$232K Sell
14,591
-19,221
-57% -$300K ﹤0.01% 1181
2022
Q3 		$553K Sell
33,812
-805
-2% -$13K ﹤0.01% 909
2022
Q2 		$488K Buy
34,617
+15,674
+83% +$293K ﹤0.01% 953
2022
Q1 		$459K Buy
18,943
+7,785
+70% +$188K ﹤0.01% 1004
2021
Q4 		$260K Buy
+11,158
New +$224K ﹤0.01% 1212

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mackenzie Financial's ACAD Position: Q2 2026 in Review

Mackenzie Financial increased its Acadia Pharmaceuticals (ACAD) stake by 315% in Q2 2026, buying an estimated $7.03M and bringing the position to 420,825 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #619.

Mackenzie Financial first reported a position in ACAD in Q4 2021 and has held it in 19 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Mackenzie Financial held 420,825 shares of Acadia Pharmaceuticals worth $10.6M as of Q2 2026.
  • Mackenzie Financial bought 319,488 Acadia Pharmaceuticals shares in Q2 2026, an estimated $7.03M.
  • Acadia Pharmaceuticals made up 0.01% of Mackenzie Financial's portfolio in Q2 2026, its #619 holding.
  • Mackenzie Financial first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.